Ann Gils
Publications by Year
Research Areas
Inflammatory Bowel Disease, Blood Coagulation and Thrombosis Mechanisms, Protease and Inhibitor Mechanisms, Microscopic Colitis, Immunodeficiency and Autoimmune Disorders
Most-Cited Works
- → Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease(2015)864 cited
- → Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient(2013)342 cited
- → Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease(2018)296 cited
- → The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease(2014)285 cited
- → The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent(2002)282 cited
- → Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD(2014)241 cited
- → Immunogenicity of biologics in inflammatory bowel disease(2018)225 cited
- → Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays(2012)207 cited
- → Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications(2012)203 cited
- → A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis(2014)184 cited